Drew Moghanaki: RCT for oligoprogressive stage IV cancer leveraging “pulsed” SBRT

Drew Moghanaki shared on X:

“NEW: phase II randomized clinical trial for oligoprogressive stage IV cancer leveraging “pulsed” SBRT q4w x 3 months to see if it can potentiate an intratumoral STING Agonist and mount a systemic response.

Here’s the schema. Patients can present with up to 6 “growing” metastases.

What is the study testing?

Here’s how the STING Agonist is injected.

I’m cautiously optimistic that triplet therapy is going to improve PFS. We’ll need to see the data to confirm.

This is one of the most exciting research studies I’ve ever been involved in. You can learn more about it here.

Read further.
Source: Drew Moghanaki/X

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).